Cell & gene therapy

Despite their potential to change the face of medicine, reducing long-term medical costs and curing diseases, innovations in cell and gene therapy face regulatory issues, along with the need for long-term studies, before market acceptance can be achieved.  

Research in this important field is undergoing rapid growth. However, due to the significant costs and timescales involved in gaining approval, effective IP strategies must be established to protect investment and maintain market position. 

Working across academic research institutes, SMEs and large multinationals, HGF’s specialist cell and gene therapy attorneys tap into their vast experience to develop robust and tailored IP strategies for their clients in this field. The team has extensive experience in helping organisations protect and exploit their IP and assess their freedom to operate.

Latest updates

How Low Can You Go? T 0137/24, Percentage Sequence Identity Claims and Divergent EPO and USPTO Approaches

Key takeaways Increasing percentage sequence identity thresholds may be selected from a disclosed convergent list without adding matter, provided the amendment does not create a new technical combination; Broader percentage …

Read article

Designing the Exit: IP Strategy for Venture-Backed Biotech

In venture-built biotech, value is not created at the point of exit, but is designed into the asset from the very beginning. The earliest decisions made around a scientific discovery …

Read article

Five Questions VCs Should Ask About IP Before They Invest

Intellectual property diligence too often starts with the wrong question: how many patents does the company have? For venture investors, that is rarely the most revealing answer. The real issue …

Read article
Event - 22nd September 2026

HGF are sponsors of LSPN Europe 2026

HGF is proud to sponsor LSPN Europe 2026, the premier event for IP professionals in the life sciences sector. Join us on September 22-23 in Basel for two days packed …

Event details
HGF logo

HGF in Conversation: Andrew Tindall on the IP Landscape of Personalised Medicine

How is the convergence of genomics, AI, diagnostics and gene therapies reshaping healthcare, and what does this mean for intellectual property? Andrew Tindall, Patent Director at HGF, recently joined Parola …

Read article
HGF logo

PRESS RELEASE - HGF strengthens Life Sciences practice with appointment of Dr Russell Thom

HGF has strengthened its European Life Sciences practice with the appointment of Dr Russell Thom, who joins the firm as a Partner 1st August 2026. Russell brings more than 25 …

Read article

Agritech Thymes: EU Adopts New NGT Regulation: Key IP Takeaways for the Agritech Sector

In a landmark moment for the European agritech sector, the EU Parliament has adopted new rules governing plants developed using New Genomic Techniques (NGTs). For developers, seed companies, and their …

Read article

Six Sectors. Six Golds. Financial Times: Europe’s Leading Patent Law Firms 2026

HGF has once again been recognised with ‘Gold’ rankings across all six sectors in the Financial Times Special Report – Europe’s Leading Patent Law Firms 2026. We are one of …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our cell & gene therapy specialists.